BioMedNewsBreaks

MondayApr 20, 2026 3:00 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach 

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader  Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that early clinical trials revealed a disconnect between IV-based delivery and the daily realities of patients with chronic rare diseases, prompting a shift toward a more practical, home-based subcutaneous approach. According to Schaber, operational challenges such as travel burden, treatment scheduling, and patient retention should be…

Continue Reading

FridayApr 17, 2026 1:24 pm

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear…

Continue Reading

FridayApr 17, 2026 12:41 pm

BioMedNewsBreaks — Why Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Is ‘One to Watch’

Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.”…

Continue Reading

FridayApr 17, 2026 9:10 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes To view the full press release, visit https://ibn.fm/9iNYY About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the…

Continue Reading

ThursdayApr 16, 2026 9:49 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports FY 2025 Net Income of $249 Million 

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on orphan oncology and advanced drug platforms, reported financial results for the fiscal year ended Dec. 31, 2025, with net income of approximately $249.0 million compared to a net loss of $4.8 million in FY 2024, primarily driven by a non-cash gain of approximately $365.4 million from the increased valuation of its GMP Biotechnology joint venture, partially offset by a deferred tax provision of $111.6 million. To view the full press release, visit https://ibn.fm/FciEs About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State…

Continue Reading

WednesdayApr 15, 2026 12:21 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Advancing Multi-Platform Healthcare Strategy

Earth Science Tech (OTC: ETST), a strategic holding company, was featured in a recent article that discussed its strives to build value by acquiring and actively managing businesses. The publication reads, “Earth Science Tech takes an approach that prioritizes capital discipline, execution, and long-term value creation across the platforms it operates, while focusing on scaling businesses that can grow sustainably and increase shareholder value. The wholly owned and majority-owned subsidies that the company operates include: Mister Meds LLC: A compounding pharmacy that delivers personalized wellness plans and dedicated support to patients across the USA… RxCompoundStore.com LLC: Another compounding pharmacy that’s authorized…

Continue Reading

WednesdayApr 15, 2026 12:10 pm

BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement 

Polyrizon (NASDAQ: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor, generating approximately $3.5 million in gross proceeds. The transactions included the sale of 388,888 units or pre-funded units at a combined price of $9.00 per unit, consisting of ordinary shares or pre-funded warrants and common warrants, with additional pre-funded and common warrants issued in the private placement, as the company plans to use proceeds for working capital and general corporate purposes, while Aegis Capital Corp. acted as exclusive placement agent. To view…

Continue Reading

WednesdayApr 15, 2026 9:59 am

BioMedNewsBreaks — MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Engages Venture Liquidity Providers for Market-Making Services 

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.  MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company focused on AI-driven voice analytics for drug and alcohol intoxication detection, announced it has appointed Venture Liquidity Providers (VLP), subject to regulatory and final approvals, to provide market-making services aimed at maintaining an orderly trading market for its common shares. The service will be conducted through W.D. Latimer Co. Ltd. in compliance with Canadian Securities Exchange policies, with MindBio agreeing to pay $5,000 per month over a 12-month term, which may be terminated at any time, while both parties operate at arm’s length and…

Continue Reading

WednesdayApr 15, 2026 9:45 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications

NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing combined neuroplastic treatments using D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with support from Chief Medical Innovation Officer Dr. Joshua Brown, and aims to pursue non-dilutive government and institutional funding while developing deployable solutions for military and first responder use, including a prototype in partnership with Zeta Surgical Inc. expected to be unveiled at the Clinical TMS…

Continue Reading

WednesdayApr 15, 2026 9:15 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Launches Proposed Public Offering to Support Commercialization and AI Initiatives

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents, with all securities to be offered by the company and the final size and terms subject to market conditions. The company said it intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities and support working capital and general corporate purposes, with Titan Partners, a division of…

Continue Reading